Status | Study |
Completed |
Study Name: the Impact of Paediatric Use of Proton Pump Inhibitors on the Risk of Community Acquired Infections. Condition: Community Infections Date: 2017-04-26 Interventions: Other: all children with at least one prescription of PPI |
Recruiting |
Study Name: Molecular Typing of Community-acquired Pneumonia Based on Multiple-omic Data Analysis Condition: Respiratory Infections Genetic Disorder Date: 2017-03-15 |
Recruiting |
Study Name: CA-MRSA Infection in China: Epidemiology, Molecular Characteristics, Treatment, and Outcome Condition: Community-Acquired Infections Methicillin-resistant Staphylococ Date: 2017-02-22 Interventions: Other: None Intervention It is observational study, no interventios to any of the three study arms |
Enrolling by invitation |
Study Name: Infection Detection by Breath Analysis Condition: Infection, Community-Acquired Communicable Disease Respira Date: 2016-11-30 |
Not yet recruiting |
Study Name: Avoidable Readmissions For Patients Hospitalized With Community-Acquired Pneumonia Condition: Community-acquired Pneumonia Date: 2016-07-11 |
Active, not recruiting |
Study Name: Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13) Condition: Bacterial Pneumonia Community-Acquired Infections Date: 2015-07-14 Interventions: Drug: Omadacycline Injection f |
Recruiting |
Study Name: Community Acquired Bacteremic Syndromes in Young Nigerian Children Condition: Community-Acquired Infections Date: 2014-12-01 |
Completed |
Study Name: Community-Onset Bacteremia Due to ESBL Producing E.Coli or K.Pneumoniae in China: Prevalence, Risk Factors and Prognosis Condition: Community Acquired Infection Date: 2013-09-30 Interventions: Other: bacteremia caused by ESBL producing E.coli or K.pneumoniae community-onset bacteremia caused by E |
Terminated |
Study Name: A Four Part Study to Investigate Relative Bioavailability, Safety and Tolerability of up to 5 Oral Formulation of GSK2251052 in Order to Identify a Formulation for Further Evaluation in a Future Later Phase Study Condition: Community-acquired Infection Date: 2012-09-20 Interventions: Drug: GSK2251052 Oral formulation of an an antibacterial |
Completed |
Study Name: Community-acquired Pneumonia in Buskerud County in Norway Condition: Community-Acquired Infections Pneumonia Date: 2012-03-22 |